Last reviewed · How we verify
Chronic antibioticrefractory ileal pouchitis
Approved treatments
- Entyvio · Takeda
Vedolizumab is a humanized monoclonal antibody that binds α4β7 integrin and blocks its interaction with MAdCAM-1, preventing memory T-lymphocyte migration into inflamed gastrointestinal tissue.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Chronic antibioticrefractory ileal pouchitis patent landscape — cliff calendar, originator estates, attackable patents
- Chronic antibioticrefractory ileal pouchitis treatment landscape brief
- Chronic antibioticrefractory ileal pouchitis treatment updates RSS
Frequently asked questions about Chronic antibioticrefractory ileal pouchitis
What drugs treat Chronic antibioticrefractory ileal pouchitis?
Tracked treatments include Entyvio.
What is the treatment for Chronic antibioticrefractory ileal pouchitis?
Standard treatment for Chronic antibioticrefractory ileal pouchitis includes Entyvio. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Chronic antibioticrefractory ileal pouchitis patent cliff · Chronic antibioticrefractory ileal pouchitis CI report
- Treatment: Entyvio · Takeda
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing